RecruitingCarcinoma, Renal Cell
Autologous Dendritic Cell Vaccine in Kidney Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
Sponsor: Jodi Maranchie
You may qualify if…
- ✓ 1. Histologically proven clear cell renal cancer that is non-metastatic and amenable to surgical resection with no evidence of metastatic disease or lesions outside of the kidney.
- ✓ 2. 18 years or older (male or female) with an ECOG performance status of 0 or 1.
- ✓ 3. Have serotype HLA-A2+ if receiving vaccine.
- ✓ 4. Capable of understanding and complying with the protocol requirements and have signed the informed consent document.
- ✓ 5. Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:
- ✓ 1. Absolute neutrophil count (ANC) ≥ 1500/µL without granulocyte colony- stimulating factor support.
- ✓ 2. White blood cell count ≥ 2500/µL.
- ✓ 3. Platelets ≥ 100,000/µL without transfusion.
You may not qualify if…
- ✕ 1. Current (within the preceding 6 weeks) treatment with systemic immunosuppressive agents including steroids except when they are administered as replacement therapy for endocrine dysfunction and do not exceed 10 mg prednisone or equivalent daily.
- ✕ 2. Known or suspected metastatic disease.
- ✕ 3. Active Hepatitis B or Hepatitis C infection or any other active infection requiring intravenous therapy.
- ✕ 4. Blood transfusion within two weeks prior to leukapheresis.
- ✕ 5. Prior treatment with cabozantinib.
- ✕ 6. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within two weeks before first dose of study treatment.
- ✕ 7. Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) within four weeks before first dose of study treatment.
- ✕ 8. Radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
Where it's recruiting
Pennsylvania
Pittsburgh
Source: ClinicalTrials.gov · NCT05127824 · last updated 2026-07-07